Humacyte (NASDAQ:HUMA) Stock Price Expected to Rise, Barclays Analyst Says

Humacyte (NASDAQ:HUMA) had its price objective lifted by equities research analysts at Barclays from $0.50 to $0.60 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Barclays‘s price target indicates a potential downside of 2.28% from the company’s current price.

Other analysts also recently issued research reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a report on Friday, October 2nd. HC Wainwright restated a “buy” rating on shares of Humacyte in a research report on Friday, October 16th. BTIG Research reaffirmed a “buy” rating and issued a $2.00 target price on shares of Humacyte in a report on Tuesday. Wall Street Zen downgraded shares of Humacyte from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Finally, Benchmark reduced their price target on shares of Humacyte from $2.00 to $1.00 and set a “speculative buy” rating for the company in a research report on Thursday, August 13th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $4.98.

Humacyte Price Performance

NASDAQ:HUMA traded up $0.02 during trading hours on Wednesday, hitting $0.61. The company’s stock had a trading volume of 1,938,955 shares, compared to its average volume of 7,553,928. Humacyte has a 52-week low of $0.34 and a 52-week high of $1.52. The company has a debt-to-equity ratio of 2.07, a quick ratio of 5.74 and a current ratio of 6.21. The business’s 50-day moving average is $0.49 and its two-hundred day moving average is $0.79. The company has a market capitalization of $170.57 million, a PE ratio of -1.26 and a beta of 2.64.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.05). The company had revenue of $0.41 million for the quarter, compared to analysts’ expectations of $1.04 million. Humacyte had a negative return on equity of 983.32% and a negative net margin of 4,556.29%. As a group, research analysts anticipate that Humacyte will post -0.40 EPS for the current fiscal year.

Institutional Investors Weigh In On Humacyte

Institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in Humacyte during the 2nd quarter valued at about $3,777,000. Alyeska Investment Group L.P. acquired a new position in Humacyte during the second quarter worth about $4,700,000. GSA Capital Partners LLP purchased a new stake in shares of Humacyte in the second quarter valued at about $785,000. Stonepine Capital Management LLC purchased a new stake in shares of Humacyte in the second quarter valued at about $180,506. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Humacyte in the second quarter valued at about $44,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

More Humacyte News

Investors following HUMA have been watching these news items:

• Positive Sentiment: Q3 results and sales momentum beat expectations: Humacyte reported a loss of $0.06 per share, narrower than the roughly $0.10 consensus, and revenue of $1.03 million versus estimates of $0.77 million. Symvess sales rose 151% from Q2 to $1.0 million; October sales were $0.8 million, and management expects Q4 Symvess sales to at least double Q3. Humacyte Q3 results
• Positive Sentiment: Upcoming clinical and regulatory catalysts: Humacyte plans to submit a supplemental BLA in November for ATEV in hemodialysis access. Five presentations at the November 17–21 VEITHsymposium will feature Phase 3 dialysis-access data, long-term vessel evidence and Symvess trauma experience, potentially raising awareness among vascular specialists. VEITHsymposium announcement
• Negative Sentiment: Commercial and clinical risks remain: Revenue is still small, and Symvess has a boxed warning for potentially life-threatening graft failure, along with risks including rupture, anastomotic failure and thrombosis. These factors could temper investor confidence and adoption.

About Humacyte

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for use in regenerative medicine and vascular repair. The company’s platform is designed to create implantable, off-the-shelf tissues that can be stored and used when needed without requiring the collection of tissue from the patient. Its primary product is SYMVESS, an acellular tissue-engineered vessel intended to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in the urgent treatment of extremity arterial injuries when emergency vascular reconstruction is required.